SOURCE: Kalorama Information

Kalorama Information

September 20, 2010 15:23 ET

Active Lung Cancer Vaccine Market in Next Five Years: Kalorama Reports

NEW YORK, NY--(Marketwire - September 20, 2010) - There could be as many as three vaccine treatments for lung cancer by 2015, according to a market research report from Kalorama Information. The report, "Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition," notes that one product will see an approval in three years and two more products could join shortly thereafter, setting the stage for healthy competition. The healthcare market research publisher recently forecasted a market exceeding $7 billion for vaccines treating all cancers in the next five years. Lung, cervical and prostate cancers are among the most viable areas, according to the report.

Lung cancer continues to be deadly despite a decrease in smoking in many developed countries. Worldwide, more than 1.2 million people are diagnosed with lung cancer annually, while 1.1 million people lose their battle against the disease each year. The American Cancer Society reports that the 5 year survival rate for lung cancer patients in all stages is only 15%.

"Although lung cancer continues to show steadily increasing incidence and mortality rates and is the number one cancer in terms of new cases worldwide, it is still an underserved area of therapeutic options," said Melissa Elder, analyst for Kalorama Information. "Therapeutic vaccines are a big step in providing life-saving options for these patients."

According to the report, one of the most promising products in development is Stimuvax, co-developed by Oncothyreon and Merck. The approval of Stimuvax, which Kalorama Information expects to occur in 2013, could slow the number of long-term treatment cases of lung cancer each year, offering huge health and economic benefits to the United States and other approved areas.

Kalorama Information also anticipates the approval of NovaRx Corporation's Lucanix at the end of 2013, and GlaxoSmithKline's MAGE-A3 vaccine sometime after 2015 -- both products are currently in Phase III development. If approved these products would compete directly with Merck/Oncothyreon's vaccine, increasing the competitive landscape in the lung cancer treatment segment.

More information on lung cancer vaccine developments can be found in Kalorama Information's report, "Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition," which also includes markets for and developments in other cancer areas along with forecasts, issues and company profiles. The report can be found at:

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter ( and LinkedIn (

Contact Information